Home › Entities › master_s_thesis › The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia

The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia

2012 master's thesis by Shevan Silva at University of Auckland
Place master_s_thesis Q112262494
Press Enter · cited answer in seconds

The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia

Summary

The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia is a master's thesis[1].

Key Facts

  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia authored Shevan Silva[2].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's instance of is recorded as master's thesis[3].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's publisher is recorded as ResearchSpace@Auckland[4].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's country of origin is recorded as New Zealand[5].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's publication date is recorded as +2012-00-00T00:00:00Z[6].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's main subject is recorded as biomedical sciences[7].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's Handle ID is recorded as 2292/13056[8].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's title is recorded as The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia[9].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's copyright holder is recorded as Shevan Silva[10].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's thesis submitted to is recorded as University of Auckland[11].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's on focus list of Wikimedia project is recorded as NZThesisProject[12].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's copyright status is recorded as copyrighted[13].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's online access status is recorded as closed user group[14].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's thesis committee member is recorded as Jack Flanagan[15].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's thesis committee member is recorded as Adam Patterson[16].
  • The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's thesis committee member is recorded as Jeff Smaill[17].

Body

Designation and Status

The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia's instance of is recorded as master's thesis[3].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [3] ↑ . wikidata.org.
  2. [2] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia. Retrieved May 3, 2026, from https://4ort.xyz/entity/the-design-and-characterization-of-aldo-keto-reductase-1c3-akr1c3-prodrugs-for-acute-myeloid-leukaemia
MLA “The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/the-design-and-characterization-of-aldo-keto-reductase-1c3-akr1c3-prodrugs-for-acute-myeloid-leukaemia.
BibTeX @misc{4ortxyz_the-design-and-characterization-of-aldo-keto-reductase-1c3-akr1c3-prodrugs-for-acute-myeloid-leukaemia_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia}}, year = {2026}, url = {https://4ort.xyz/entity/the-design-and-characterization-of-aldo-keto-reductase-1c3-akr1c3-prodrugs-for-acute-myeloid-leukaemia}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): The design and characterization of aldo-keto reductase 1C3 (AKR1C3) prodrugs for acute myeloid leukaemia — https://4ort.xyz/entity/the-design-and-characterization-of-aldo-keto-reductase-1c3-akr1c3-prodrugs-for-acute-myeloid-leukaemia (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/the-design-and-characterization-of-aldo-keto-reductase-1c3-akr1c3-prodrugs-for-acute-myeloid-leukaemia · Last refreshed: